Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Topical Emulgels of Pregabalin were formulated using Carbopol 940 in combination with (PVP k90, PEG 200, PEG 1000, HPMC K15M) to obtain the optimal formula in terms of drug release rate. Physical appearance, pH, viscosity, stability, drug content, In-vitro drug release, Differential scanning calorimetry and Fourier transform infrared spectroscopy, were tested in all formulas and evaluated to determine the best one. All formulations had good physical properties and stability, F2 which contains Carbopol 940 0.4% and HPMC K15M 0.4% gave the best drug release rate: (30% in 20 min and 93% in 360 min). But F3 which contains Carbopol 940 0.4% and PEG 200 10% showed the less release rate at 360 min: (64%). F2 showed Korsmeyer–Peppas model Kinetic release. So F2 was the best formula because it released drug since 10 min and still to 360 min (6 hours), thus F2 can be used to obtain rapid analgesic effect and avoid CNS-mediated side effects of Pregabalin.
Topical Emulgels of Pregabalin were formulated using Carbopol 940 in combination with (PVP k90, PEG 200, PEG 1000, HPMC K15M) to obtain the optimal formula in terms of drug release rate. Physical appearance, pH, viscosity, stability, drug content, In-vitro drug release, Differential scanning calorimetry and Fourier transform infrared spectroscopy, were tested in all formulas and evaluated to determine the best one. All formulations had good physical properties and stability, F2 which contains Carbopol 940 0.4% and HPMC K15M 0.4% gave the best drug release rate: (30% in 20 min and 93% in 360 min). But F3 which contains Carbopol 940 0.4% and PEG 200 10% showed the less release rate at 360 min: (64%). F2 showed Korsmeyer–Peppas model Kinetic release. So F2 was the best formula because it released drug since 10 min and still to 360 min (6 hours), thus F2 can be used to obtain rapid analgesic effect and avoid CNS-mediated side effects of Pregabalin.
Advanced technology is needed for quicker and better wound healing management by minimizing infection, keeping moisturizing the wound surface, speeding up tissue growth, and reducing infection at the specific area. The advancement of drug delivery in nano form is gradually increasing and shows a greater response towards healing wounds. The drug's in nano shape potential to hold the drug and facilitate rapid targeted effect in tissue growth and repair. Research outcomes confirm that shortcomings of the traditional form of dosage may be revived by nanomedicine because of its better target-specific application for wound treatment. The present analysis concentrated on further growth and applicants for medications in nano form targeting to accelerate healing of wound treatments for a different wound style. The latest development in nanomedicine has been created by different researchers in the shape of nanoparticles, niosomes, dendrimers, nanosomes, hydrogels, liposomes, and micelles, etc. which emphasize clinical value and provide better therapeutic benefits. Past few years significant development has been observed on nanomedicines to satisfy the clinical needs for chronic and wounds that are diabetic. The occurrence of wounds nonhealing gradually increasing which affects the patient mentally and financially. This current review article summarized with latest developments within the area of nanomedicine, which dramatically expanded its clinical value towards wound healing.
Imbalance of collagen synthesis and degradation causes formation of abnormal scarring leading to hypertrophic scar or keloid. Previous studies have shown that applying antihistamines could reduce the level of dermal collagen. However, no data whether topical antihistamine could be used as preventative therapy for abnormal scar formation. The aim of this study was to assess whether the application of topical antihistamine in acute wounds could affect the level of transforming growth factor beta (TGF-β), a regulator of wound healing process, and collagen in wound healing phase in order to suppress the keloid formation. A randomized post-test only control group design study was conducted. Twenty-four acute wounds on Rattus novergicus rats were randomized divided into control and treatment groups. The animals of treatment group received daily topical antihistamine consisting 1% diphenhydramine hydrochloride and 0.1% zinc acetate. The full-thickness skin tissue from each rat were taken on day 5 and 21 and were subjected to ELISA test to measure the levels of TGF-β and collagen. Our data found that in the treatment group, the level of collagen decreased significantly over time (1623.61ng/mL on day 5 to 755.15ng/mL on day 21, p=0.001). Similarly, the level of TGF- also decreased although was not statistically significant (p=0.766). In contrast, the levels of TGF-β level and collagen in the control group increased significantly from day 5 to day 21, p=0.003 and p=0.001, respectively. The level of TGF- in treatment group was significantly higher compared to the control group p=0.001 on day 21 while the level of collagen had no different between treatment and control group (p=0.124). In conclusion, our data suggest that topical antihistamine reduced the levels of TGF-β and collagen at the end of the proliferation phase or the beginning of the remodeling phase. Further study is warrant to elucidate the effect of antihistamine on other would healing markers or parameters.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.